PRME
Prime Medicine, Inc.
Price Chart
Latest Quote
$3.49
+0.02 (+0.58%)
Current Price
| Previous Close | $3.47 |
| Open | $3.47 |
| Day High | $3.52 |
| Day Low | $3.38 |
| Volume | 2,514,930 |
Stock Information
| Shares Outstanding | 180.62M |
| Total Debt | $114.51M |
| Cash Equivalents | $135.50M |
| Revenue | $4.03M |
| Net Income | $-198.37M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $565.33M |
| EPS (TTM) | $-1.20 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $544.35M |
| Sales | $4.03M |
| Income | $-198.37M |
| Book/sh | $0.42 |
| Cash/sh | $0.75 |
| Employees | 146 |
Financial Ratios
| Quick Ratio | 3.73 |
| Current Ratio | 3.80 |
| Debt/Eq | 149.30 |
Returns & Margins
| ROA | -41.46% |
| ROE | -216.06% |
| Operating Margin | -5917.52% |
Ownership
| Insider Ownership | 23.76% |
| Institutional Ownership | 66.65% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.72 |
| P/S | 140.14 |
| P/B | 7.36 |
Analyst Data
| Recommendation | buy |
| Target Price | $7.12 |
Technical Indicators
| SMA20 | $3.61 |
| SMA50 | $3.29 |
| SMA200 | $3.87 |
| RSI | 44.68 |
| ATR | 0.3793 |
| Shares Float | 114.96M |
| Short Float | 24.61% |
| Short Ratio | 10.33 |
| Volatility | 2.27 |
| Rel Volume | 0.75 |
Performance History
| Week | -17.20% |
| Month | +9.06% |
| Quarter | -14.71% |
| 6 Months | -27.38% |
| YTD | -11.33% |
| Year | -22.52% |
| 3 Years | -78.77% |
| 10 Years | -79.64% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $3.13 | 3,349,500 |
| 2026-07-16 | $3.22 | 3,678,800 |
| 2026-07-15 | $3.49 | 2,538,000 |
| 2026-07-14 | $3.47 | 3,512,800 |
| 2026-07-13 | $3.52 | 3,550,500 |
| 2026-07-10 | $3.78 | 6,656,600 |
| 2026-07-09 | $4.23 | 4,868,500 |
| 2026-07-08 | $4.62 | 11,421,900 |
| 2026-07-07 | $3.99 | 4,131,800 |
| 2026-07-06 | $3.99 | 4,452,000 |
| 2026-07-02 | $3.87 | 5,601,100 |
| 2026-07-01 | $3.89 | 3,802,300 |
| 2026-06-30 | $3.69 | 2,690,400 |
| 2026-06-29 | $3.72 | 5,294,400 |
| 2026-06-26 | $3.43 | 7,659,100 |
| 2026-06-25 | $3.18 | 2,832,300 |
| 2026-06-24 | $3.12 | 3,805,000 |
| 2026-06-23 | $3.24 | 2,965,500 |
| 2026-06-22 | $3.37 | 3,500,800 |
| 2026-06-18 | $3.23 | 3,501,600 |
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)
Insider Monkey âĸ 2026-07-15T14:01:53Z
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
Insider Monkey âĸ 2026-07-15T08:53:17Z
Cathie Wood Dumps AMD, Doubles Down on Meta Stock
GuruFocus.com âĸ 2026-07-10T12:57:14ZBeam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?
Simply Wall St. âĸ 2026-07-09T20:14:10Z
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
Investor's Business Daily âĸ 2026-07-08T20:09:06Z
PRME Surges 15% After Winning Arbitration Against Beam â Clears Path To Human Trials For Its Gene-Editing Drug
Stocktwits âĸ 2026-07-08T16:47:25Z
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
BioPharma Dive âĸ 2026-07-08T09:07:00Z
Hereâs Why H.C. Wainwright Upgraded Prime Medicine (PRME) To âBuyâ
Insider Monkey âĸ 2026-07-05T22:07:53Z
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
Zacks âĸ 2026-07-03T11:42:00Z
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-06-15T20:30:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $4,632,000 | $2,983,000 | $0 | $0 |
| Operating Revenue | $4,632,000 | $2,983,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $212,982,000 | $205,450,000 | $191,292,000 | $116,544,000 |
| Other Income Expense | $3,059,000 | $3,063,000 | $-9,931,000 | $-6,225,000 |
| Other Non Operating Income Expenses | $148,000 | $41,000 | $274,000 | $1,903,000 |
| Net Non Operating Interest Income Expense | $4,149,000 | $3,522,000 | $2,811,000 | - |
| Operating Expense | $212,982,000 | $205,450,000 | $191,292,000 | $116,544,000 |
| General And Administrative Expense | $52,346,000 | $50,161,000 | $43,387,000 | $29,819,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-201,142,000 | $-195,882,000 | $-198,133,000 | $-121,821,000 |
| Net Interest Income | $4,149,000 | $3,522,000 | $2,811,000 | - |
| Interest Income | $4,149,000 | $3,522,000 | $2,811,000 | - |
| Normalized Income | $-201,574,000 | $-195,397,000 | $-182,273,333 | $-113,749,896 |
| Net Income From Continuing And Discontinued Operation | $-201,142,000 | $-195,882,000 | $-198,133,000 | $-121,821,000 |
| Total Operating Income As Reported | $-208,350,000 | $-202,467,000 | $-204,792,000 | $-116,544,000 |
| Net Income Common Stockholders | $-201,142,000 | $-195,882,000 | $-198,133,000 | $-142,014,000 |
| Net Income | $-201,142,000 | $-195,882,000 | $-198,133,000 | $-121,821,000 |
| Net Income Including Noncontrolling Interests | $-201,142,000 | $-195,882,000 | $-198,133,000 | $-121,821,000 |
| Net Income Continuous Operations | $-201,142,000 | $-195,882,000 | $-198,133,000 | $-121,821,000 |
| Pretax Income | $-201,142,000 | $-195,882,000 | $-198,412,000 | $-122,769,000 |
| Interest Income Non Operating | $4,149,000 | $3,522,000 | $2,811,000 | - |
| Operating Income | $-208,350,000 | $-202,467,000 | $-191,292,000 | $-116,544,000 |
| Special Income Charges | - | $0 | $-13,500,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-1.35 | $-1.65 | $-2.18 | $-4.19 |
| Basic EPS | $-1.35 | $-1.65 | $-2.18 | $-4.19 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-22,333 | $-56,896 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-201,461,000 | $-195,854,000 | $-170,757,000 | $-106,192,000 |
| Total Unusual Items | $432,000 | $-485,000 | $-15,882,000 | $-8,128,000 |
| Total Unusual Items Excluding Goodwill | $432,000 | $-485,000 | $-15,882,000 | $-8,128,000 |
| Reconciled Depreciation | $7,321,000 | $6,128,000 | $4,653,000 | $2,224,000 |
| EBITDA (Bullshit earnings) | $-201,029,000 | $-196,339,000 | $-186,639,000 | $-114,320,000 |
| EBIT | $-208,350,000 | $-202,467,000 | $-191,292,000 | $-116,544,000 |
| Diluted Average Shares | $148,758,527 | $118,600,381 | $90,969,327 | $33,891,264 |
| Basic Average Shares | $148,758,527 | $118,600,381 | $90,969,327 | $33,891,264 |
| Diluted NI Availto Com Stockholders | $-201,142,000 | $-195,882,000 | $-198,133,000 | $-142,014,000 |
| Securities Amortization | $-2,479,000 | $-3,507,000 | $-5,677,000 | - |
| Gain On Sale Of Security | $432,000 | $-485,000 | $-2,382,000 | $-8,128,000 |
| Research And Development | $160,636,000 | $155,289,000 | $147,905,000 | $86,725,000 |
| Selling General And Administration | $52,346,000 | $50,161,000 | $43,387,000 | $29,819,000 |
| Other Gand A | $29,320,000 | $23,592,000 | $26,311,000 | $18,725,000 |
| Salaries And Wages | $23,026,000 | $26,569,000 | $17,076,000 | $11,094,000 |
| Tax Provision | - | $0 | $-279,000 | $-948,000 |
| Other Special Charges | - | - | $13,500,000 | - |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
| Preferred Stock Dividends | - | - | - | $20,193,000 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $120,868,000 | $153,149,000 | $133,071,000 | $316,270,000 |
| Total Assets | $342,733,000 | $297,508,000 | $193,851,000 | $360,314,000 |
| Total Non Current Assets | $161,440,000 | $85,622,000 | $50,875,000 | $63,696,000 |
| Other Non Current Assets | $14,691,000 | $14,062,000 | $14,275,000 | $15,142,000 |
| Current Assets | $181,293,000 | $211,886,000 | $142,976,000 | $296,618,000 |
| Other Current Assets | $674,000 | $14,667,000 | $2,254,000 | $246,000 |
| Prepaid Assets | $2,939,000 | $6,777,000 | $19,057,000 | $2,451,000 |
| Cash Cash Equivalents And Short Term Investments | $177,680,000 | $190,442,000 | $121,665,000 | $293,921,000 |
| Cash And Cash Equivalents | $63,032,000 | $182,476,000 | $41,574,000 | $187,620,000 |
| Debt | ||||
| Total Debt | $116,427,000 | $40,794,000 | $13,633,000 | $28,745,000 |
| Long Term Debt And Capital Lease Obligation | $108,290,000 | $37,180,000 | $4,357,000 | $17,051,000 |
| Current Debt And Capital Lease Obligation | $8,137,000 | $3,614,000 | $9,276,000 | $11,694,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $221,865,000 | $144,359,000 | $60,780,000 | $44,044,000 |
| Total Non Current Liabilities Net Minority Interest | $184,417,000 | $106,398,000 | $4,357,000 | $17,330,000 |
| Non Current Deferred Liabilities | $76,127,000 | $69,218,000 | $0 | $279,000 |
| Current Liabilities | $37,448,000 | $37,961,000 | $56,423,000 | $26,714,000 |
| Other Current Liabilities | $1,704,000 | $1,272,000 | $2,639,000 | $449,000 |
| Current Deferred Liabilities | $7,824,000 | $7,092,000 | $0 | - |
| Payables And Accrued Expenses | $12,446,000 | $17,007,000 | $36,238,000 | $8,042,000 |
| Payables | $8,887,000 | $11,351,000 | $19,537,000 | $4,332,000 |
| Accounts Payable | $8,887,000 | $11,351,000 | $19,537,000 | $4,332,000 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $279,000 |
| Equity | ||||
| Common Stock Equity | $120,868,000 | $153,149,000 | $133,071,000 | $316,270,000 |
| Total Equity Gross Minority Interest | $120,868,000 | $153,149,000 | $133,071,000 | $316,270,000 |
| Stockholders Equity | $120,868,000 | $153,149,000 | $133,071,000 | $316,270,000 |
| Gains Losses Not Affecting Retained Earnings | $82,000 | $1,000 | $-15,000 | $-384,000 |
| Other Equity Adjustments | $82,000 | $1,000 | $-15,000 | - |
| Retained Earnings | $-888,354,000 | $-687,212,000 | $-491,330,000 | $-293,197,000 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $180,514,014 | $131,160,842 | $97,377,121 | $97,209,213 |
| Share Issued | $180,514,014 | $131,160,842 | $97,377,121 | $97,209,213 |
| Tangible Book Value | $120,868,000 | $153,149,000 | $133,071,000 | $316,270,000 |
| Invested Capital | $120,868,000 | $153,149,000 | $133,071,000 | $316,270,000 |
| Working Capital | $143,845,000 | $173,925,000 | $86,553,000 | $269,904,000 |
| Capital Lease Obligations | $116,427,000 | $40,794,000 | $13,633,000 | $28,745,000 |
| Total Capitalization | $120,868,000 | $153,149,000 | $133,071,000 | $316,270,000 |
| Additional Paid In Capital | $1,009,138,000 | $840,358,000 | $624,414,000 | $609,849,000 |
| Capital Stock | $2,000 | $2,000 | $2,000 | $2,000 |
| Common Stock | $2,000 | $2,000 | $2,000 | $2,000 |
| Non Current Deferred Revenue | $76,127,000 | $69,218,000 | $0 | - |
| Long Term Capital Lease Obligation | $108,290,000 | $37,180,000 | $4,357,000 | $17,051,000 |
| Current Deferred Revenue | $7,824,000 | $7,092,000 | $0 | - |
| Current Capital Lease Obligation | $8,137,000 | $3,614,000 | $9,276,000 | $11,694,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,337,000 | $8,976,000 | $8,270,000 | $6,529,000 |
| Current Accrued Expenses | $3,559,000 | $5,656,000 | $16,701,000 | $3,710,000 |
| Net PPE | $146,749,000 | $71,560,000 | $36,600,000 | $48,554,000 |
| Accumulated Depreciation | $-20,434,000 | $-13,597,000 | $-7,484,000 | $-2,831,000 |
| Gross PPE | $167,183,000 | $85,157,000 | $44,084,000 | $51,385,000 |
| Leases | $7,911,000 | $5,136,000 | $579,000 | $564,000 |
| Construction In Progress | $365,000 | $3,578,000 | $5,402,000 | $1,608,000 |
| Other Properties | $155,921,000 | $74,499,000 | $37,814,000 | $48,967,000 |
| Machinery Furniture Equipment | $2,986,000 | $1,944,000 | $289,000 | $246,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $114,648,000 | $7,966,000 | $80,091,000 | $106,301,000 |
| Preferred Stock | - | - | - | $0 |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-167,095,000 | $-130,159,000 | $-174,136,000 | $-147,922,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-162,564,000 | $-122,865,000 | $-165,412,000 | $-131,827,000 |
| Cash Flow From Continuing Operating Activities | $-162,564,000 | $-122,865,000 | $-165,412,000 | $-131,827,000 |
| Operating Gains Losses | - | - | $28,000 | $8,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,531,000 | $-7,294,000 | $-8,724,000 | $-16,095,000 |
| Investing Cash Flow | $-108,763,000 | $68,457,000 | $18,711,000 | $-47,096,000 |
| Cash Flow From Continuing Investing Activities | $-108,763,000 | $68,457,000 | $18,711,000 | $-47,096,000 |
| Net Other Investing Changes | - | $1,000,000 | $-170,000 | $-665,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $138,390,000 | $170,136,000 | $0 | $185,317,000 |
| Financing Cash Flow | $151,512,000 | $195,876,000 | $655,000 | $181,494,000 |
| Cash Flow From Continuing Financing Activities | $151,512,000 | $195,876,000 | $655,000 | $181,494,000 |
| Net Other Financing Charges | $12,000,000 | $6,000,000 | - | $-4,042,000 |
| Net Common Stock Issuance | $138,390,000 | $170,136,000 | $0 | $185,317,000 |
| Common Stock Issuance | $138,390,000 | $170,136,000 | $0 | $185,317,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $76,723,000 | $196,538,000 | $55,070,000 | $201,116,000 |
| Beginning Cash Position | $196,538,000 | $55,070,000 | $201,116,000 | $198,545,000 |
| Changes In Cash | $-119,815,000 | $141,468,000 | $-146,046,000 | $2,571,000 |
| Proceeds From Stock Option Exercised | $1,122,000 | $19,740,000 | $655,000 | $219,000 |
| Net Investment Purchase And Sale | $-104,232,000 | $74,751,000 | $27,605,000 | $-30,336,000 |
| Sale Of Investment | $101,181,000 | $204,200,000 | $132,556,000 | $93,000,000 |
| Purchase Of Investment | $-205,413,000 | $-129,449,000 | $-104,951,000 | $-123,336,000 |
| Net PPE Purchase And Sale | $-4,531,000 | $-7,294,000 | $-8,724,000 | $-16,095,000 |
| Purchase Of PPE | $-4,531,000 | $-7,294,000 | $-8,724,000 | $-16,095,000 |
| Change In Working Capital | $-5,340,000 | $31,076,000 | $2,647,000 | $-35,401,000 |
| Change In Other Working Capital | $-4,359,000 | $70,310,000 | - | - |
| Change In Other Current Liabilities | $-5,362,000 | $-6,461,000 | $-12,296,000 | $-10,248,000 |
| Change In Payables And Accrued Expense | $-164,000 | $-16,914,000 | $24,398,000 | $-23,415,000 |
| Change In Accrued Expense | $-1,160,000 | $-11,657,000 | $15,258,000 | $-25,873,000 |
| Change In Payable | $996,000 | $-5,257,000 | $9,140,000 | $2,458,000 |
| Change In Account Payable | $996,000 | $-5,257,000 | $9,140,000 | $2,458,000 |
| Change In Prepaid Assets | $4,545,000 | $-15,859,000 | $-9,455,000 | $-1,738,000 |
| Other Non Cash Items | $9,698,000 | $12,355,000 | $12,788,000 | $9,790,000 |
| Stock Based Compensation | $29,268,000 | $26,068,000 | $13,910,000 | $6,459,000 |
| Unrealized Gain Loss On Investment Securities | $-432,000 | $484,000 | $2,382,000 | $8,128,000 |
| Amortization Of Securities | $-1,937,000 | $-3,094,000 | $-3,408,000 | $-250,000 |
| Depreciation Amortization Depletion | $7,321,000 | $6,128,000 | $4,653,000 | $2,224,000 |
| Depreciation And Amortization | $7,321,000 | $6,128,000 | $4,653,000 | $2,224,000 |
| Depreciation | $7,321,000 | $6,128,000 | $4,653,000 | $2,224,000 |
| Net Income From Continuing Operations | $-201,142,000 | $-195,882,000 | $-198,133,000 | $-121,821,000 |
| Deferred Tax | - | $0 | $-279,000 | $-964,000 |
| Deferred Income Tax | - | $0 | $-279,000 | $-964,000 |
| Gain Loss On Sale Of PPE | - | $0 | $28,000 | $8,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $141,000 |
Fetched: 2026-07-16